TrialCancer immunology, immunotherapy : CII2026

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.

Zhenggang Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.